Chronic Hepatitis C Genotype 1 6 Therapeutics
1. Sovaldi patent expiration
Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 2, 3 or 4 chronic hepatitis c virus (hcv) infection as a component of a combination antiviral treatment regimen with ribavirin
SOVALDI's oppositions filed in EPO
SOVALDI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9085573 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
| US8580765 | GILEAD SCIENCES INC | NA |
Mar, 2028
(2 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(3 years from now) | |
| US8618076 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Dec, 2030
(4 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(4 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8618076 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Jun, 2031
(5 years from now) | |
|
US9284342 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2031
(5 years from now) | |
|
US9085573 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(2 years from now) | |
|
US8633309 (Pediatric) | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2029
(3 years from now) | |
|
US8889159 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(3 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(3 years from now) | |
| US9549941 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(3 years from now) | |
|
US8580765 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(2 years from now) | |
|
US7964580 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2029
(3 years from now) | |
|
US8334270 (Pediatric) | GILEAD SCIENCES INC | NA |
Sep, 2028
(2 years from now) | |
|
US9549941 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 06, 2018 |
| New Patient Population(NPP) | Apr 07, 2020 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| ODE*(ODE*) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-135) | Apr 07, 2024 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| Orphan Drug Exclusivity(ODE-258) | Aug 28, 2026 |
Drugs and Companies using SOFOSBUVIR ingredient
Market Authorisation Date: 28 August, 2019
Dosage: PELLETS; TABLET
How can I launch a generic of SOVALDI before it's drug patent expiration?
More Information on Dosage
SOVALDI family patents
